Neurocrine Biosciences Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Good morning. Thanks for joining us at the Bank of America Merrill Lynch Conference. I am Tazeen Ahmad. I'm the senior SMid biotech analyst here. It's my pleasure to introduce our next presenting company. Sitting next to me are 2 of the members of the management team from Neurocrine: Kevin Gorman, who is the Chief Executive Officer; as well as Matt Abernethy, who's Chief Financial Officer.
The format is going to be Q&A. So feel free to raise your hand if you have any questions from the audience. But maybe Kevin, for those few people who don't know that much about Neurocrine, maybe for 2 minutes, you can tell us about the company and where you're at, and we can go from there.
Sure. Thank you, Tazeen, and thank you, Bank of America, for the invitation to speak here today. I don't have a slide for it, but we will be making forward-looking statements. So I'd like to direct you to our recent SEC filings for all the cautions and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |